141P Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: A systematic review and meta-analysis

The role of concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer remains controversial. This systematic review and meta-analysis was conducted to better assess the efficacy safety this strategy patients cancer. trials which were randomly assigned receive alone or eligible for inclusion. Prime endpoint pathological complete response (pCR) rate. Clinical (complete clinical response: CR, partial PR) secondary endpoints. A random effects model used perform statistical analyses. total 695 from five included. PCR rate 10.34% group 7.78% control (OR=1.40, 95%CI 0.71-2.75, P=0.33). CR 15.65% 10.20% (OR=1.66, 0.99-2.79, P=0.05). ORR (CR+PR) significantly higher than ( 79.42%(274/345) vs. 69.97%(240/343) , OR=1.69, 1.19-2.42, P=0.004) approach showed no heterogeneity(I2=0%, P=0.54) . Concurrent tamoxifen could potentially increase occurrence adverse events while aromatase inhibitors (AIs) would not. Our findings provide evidence as an available option achieve a compared low toxicity.